Update on the role of FeNO in asthma management
Asthma is a heterogenous disorder characterized by presence of different phenotypes and
endotypes. Up to 10% of the individuals suffer from severe asthma and are at increased risk …
endotypes. Up to 10% of the individuals suffer from severe asthma and are at increased risk …
Exploring the interaction between fractional exhaled nitric oxide and biologic treatment in severe asthma: A systematic review
T Pianigiani, L Alderighi, M Meocci, M Messina… - Antioxidants, 2023 - mdpi.com
Background: Fractional exhaled nitric oxide (FeNO) is a biomarker of airway inflammation
associated with airway hyper-responsiveness and type-2 inflammation. Its role in the …
associated with airway hyper-responsiveness and type-2 inflammation. Its role in the …
Utilizing predictive inflammatory markers for guiding the use of biologicals in severe asthma
M Runnstrom, H Pitner, J Xu, FEH Lee… - Journal of …, 2022 - Taylor & Francis
Asthma is a chronic respiratory disease characterized by chronic airway inflammation and
airflow obstruction. Up to ten percent of asthmatics have severe asthma, and many remain …
airflow obstruction. Up to ten percent of asthmatics have severe asthma, and many remain …
Use of FeNO to predict anti-IL-5 and IL-5R biologics efficacy in a real-world cohort of adults with severe eosinophilic asthma
C Menigoz, S Dirou, A Chambellan, D Hassoun… - Journal of …, 2023 - Taylor & Francis
Introduction Severe eosinophilic asthma (SEA) is associated with multiple exacerbations.
Fractional exhaled nitric oxide (FeNO), a biomarker of airway T2 inflammation, is known to …
Fractional exhaled nitric oxide (FeNO), a biomarker of airway T2 inflammation, is known to …
Anti-IL-5 and anti-IL-5R biologics for severe asthma. Are there any differences in their effects?
P Granda, E Villamañán, C Carpio, D Laorden… - Journal of …, 2024 - Taylor & Francis
Objective The aim of this retrospective multicentre study is to describe the clinical
characteristics of patients diagnosed with severe eosinophilic asthma receiving anti-IL-5/anti …
characteristics of patients diagnosed with severe eosinophilic asthma receiving anti-IL-5/anti …
Increase in FeNO levels following IL5/IL5R-targeting therapies in severe asthma: a case series
G Pelletier, K Godbout, MÈ Boulay… - Journal of Asthma …, 2022 - Taylor & Francis
Purpose Monoclonal antibodies targeting interleukin-5 (IL5) and its receptor (IL5R), used for
severe asthma treatment, reduce eosinophils to almost complete depletion. Fractional …
severe asthma treatment, reduce eosinophils to almost complete depletion. Fractional …
Evaluation of Multiple-Flows Exhaled Nitric Oxide and Its Clinical Significance in Severe Asthmatic Patients Treated with Biologics: A Prospective Real-Life Study
T Pianigiani, S Luzzi, A Dilroba, M Meocci… - Journal of …, 2024 - Taylor & Francis
BACKGROUND: Specific biomarkers, such as eosinophilia in peripheral blood or fractional
exhaled nitric oxide (FeNO), can guide us in the choice of biologic therapy, allowing a more …
exhaled nitric oxide (FeNO), can guide us in the choice of biologic therapy, allowing a more …
The clinical effectiveness of mepolizumab treatment in severe eosinophilic asthma; outcomes from four years cohort evaluation
C Reilly, A Raja, P Anilkumar, J Sullivan, L White… - Journal of …, 2024 - Taylor & Francis
Background Clinical trials and real world studies demonstrated benefit of mepolizumab
treatment in severe asthma but data on its effectiveness beyond 2 years remain limited …
treatment in severe asthma but data on its effectiveness beyond 2 years remain limited …
[HTML][HTML] The role of nitric oxide in pleural disease
Nitric oxide (NO) regulates various physiological and pathophysiological functions in the
lungs. However, there is much less information about the effects of NO in the pleura. The …
lungs. However, there is much less information about the effects of NO in the pleura. The …